c Nonculture-based tests are gaining popularity in the diagnosis of invasive fungal disease (IFD), but PCR is excluded from disease-defining criteria because of limited standardization and a lack of commercial assays. Commercial PCR assays may have a standardized methodology while providing quality assurance. The detection of PCR products by a surface-enhanced Raman scattering (SERS) assay potentially provides superior analytical sensitivity and multiplexing capacity compared to that of realtime PCR. Using this approach, the RenDx Fungiplex assay was developed to detect Candida and Aspergillus. Analytical and clinical evaluations of the assay were undertaken using extraction methods according to European Aspergillus PCR Initiative (EAPCRI) recommendations. A total of 195 previously extracted samples (133 plasma, 49 serum, and 13 whole blood) from 112 patients (29 with proven/probable IFD) were tested. The 95% limit of detection of Candida and Aspergillus was 200 copies per reaction, with an overall reproducibility of 92.1% for detecting 20 input copies per PCR, and 89.8% for the nucleic acid extraction-PCR-SERS process for detecting fungal burdens of <20 genome equivalents per sample. A clinical evaluation showed that assay positivity significantly correlated with IFD (P < 0.0001). The sensitivity of the assay was 82.8% and was similar for both Candida (80.0%) and Aspergillus (85.7%). The specificity was 87.5% and was increased (97.5%) by using a multiple (>2 samples) PCR-positive threshold. In summary, the RenDx Fungiplex assay is a PCR-SERS assay for diagnosing IFD and demonstrates promising clinical performance on a variety of samples. This was a retrospective clinical evaluation, and performance is likely to be enhanced through a prospective analysis of clinical validity and by determining clinical utility.
T he use of nonculture-based tests can enhance the diagnosis of invasive fungal disease (IFD) (1, 2) . While antigen detection (galactomannan enzyme immunoassay [EIA] and [1, 3] -␤-D-glucan) is widely used, molecular-based detection (PCR) has been excluded from the revised European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) disease-defining criteria; this is a consequence of limited standardization and a paucity of commercially manufactured assays (3) .
Since the publication of the disease-defining criteria, there have been several advances to standardize molecular diagnostics. The minimum information required for the publication of quantitative PCR experiments (MIQE) guidelines have been proposed in order to provide a standardized generic approach when developing and reporting real-time PCR assays (4) . Specific to mycology, the European Aspergillus PCR initiative (EAPCRI) has offered recommendations to provide optimal methodology when testing whole-blood and serum samples by Aspergillus PCR (5, 6 ). An international standard has been developed, providing reference material for assay comparison and validation (7) .
Commercial assays have become available for diagnosing invasive aspergillosis (IA) and invasive candidiasis (IC), providing standardized methodology and quality-controlled development in line with commercially available antigen-based tests (8) (9) (10) . Most commercial PCR tests utilize real-time technology, providing rapid results for an individual target or a limited number of targets plus an internal control in a single reaction. Multiplexing is restricted by the limited number of fluorescent channels available on the PCR platform. Consequently, they are often inadequate for syndromic approaches, for which performing multiple PCRs per sample is neither cost-nor time-efficient. When real-time technology has been applied, for example, in the investigation of sepsis using the Roche SeptiFast assay, cases of IFD have been limited, providing only anecdotal information regarding performance (11, 12) .
Recently, a novel approach to genotyping human papillomavirus infection utilized surface-enhanced Raman scattering (SERS) (13) . SERS uses sensitive spectroscopic detection to generate analyte-specific fingerprint spectra and is particularly suited to the simultaneous detection of multiple targets (14) .
To provide a standardized diagnostic approach, a new SERS spectroscopy platform, RenDx (Renishaw Diagnostics Limited, Glasgow, United Kingdom), has been developed for detecting nucleic acid targets, including semiautomated postamplification processing and multiplex detection using Raman spectroscopy, and it is capable of detecting up to 10 targets per reaction. Using purpose-designed assays, or by modifying existing PCR protocols, SERS detection can differentiate between multiple etiological targets by detecting the presence of oligonucleotides specific for each pathogen. The essential components for a screening assay targeting a low-incidence disease are high sensitivity and concordant negative predictive value to exclude disease. SERS multiplexing capacity and analytical sensitivity have the potential to exceed fluorescent-based technologies, making it ideal for such an application (14) .
Using this approach, an assay was developed (RenDx Fungiplex) for diagnosing IA using a generic Aspergillus probe, and for diagnosing IC by combining a broad-range Saccharomycetales yeast probe with a probe specific for pathogenic species belonging to the diploid arm of the Candida clade (C. albicans, C. dubliniensis, C. parapsilosis, and C. tropicalis) (15) . The assay has the added benefit of differentiating potentially antifungal-resistant species (Candida glabrata, Candida krusei, and Aspergillus terreus) through specific probes. This paper describes the process of analytical and clinical evaluations of the assay when testing multiple sample types, as well as nucleic acid (NA) extraction methods in keeping with EAPCRI recommendations.
MATERIALS AND METHODS
Analytical performance. A summary of the process used to determine analytical performance is shown in Fig. 1 .
Determining the limit of detection of PCR-SERS. To evaluate the limit of detection (LOD) of PCR amplification combined with SERS detection, 40 replicates of two concentrations (200 and 20 copies per PCR) and nine replicates of two lower concentrations (2 and 1 copy per PCR) of quantified plasmids containing the 18S or 28S rRNA PCR target, for a range of Candida and Aspergillus species, respectively, were tested. To determine assay robustness, PCR amplification of the two higher concentrations (200 and 20 copies per reaction) was performed on five separate occasions using four different types of PCR instruments (Bio-Rad MyCycler X2, Bio-Rad T100, Applied Biosystems Veriti, and GRI G-Storm); replicate testing was split equally (n ϭ 8) across the platforms (Table 1) . At the lower concentrations (2 and 1 copy per reaction), amplification was performed on the Bio-Rad MyCycler only.
Determining the limit of detection of the entire molecular process (extraction-PCR-SERS detection). To investigate the influence of NA extraction on the LOD, various simulated sample types (EDTA whole blood [WB] , serum, and plasma) containing clinically relevant concentrations (100 to 10 genome equivalents per ml of sample) of the pertinent fungal pathogens were prepared. A total of 93 simulated samples were tested ( Table 2 ). The WB samples were spiked with quantified fungal organism (Aspergillus conidia or Candida blastospore), whereas genomic DNA was used for the serum/plasma samples. NA was extracted according to EAPCRI recommendations (5, 6) . Three-milliliter samples of WB were extracted using red and white blood cell lysis, followed by mechanical disruption of the fungal cells by bead beating and automated NA purification/precipitation using the tissue kit on the Qiagen EZ1 Advanced XL instrument (Qiagen, United Kingdom). For serum/plasma, NA was extracted from 0.5-ml volumes using the Qiagen EZ1 DSP virus kit on the same platform. All NA was eluted in 50 to 60 l. PCR amplification was performed using the Applied Biosystems Veriti instrument (Life Technologies, United Kingdom) (Fig. 2) .
Determining the range of detection and cross-reactivity. To determine the analytical specificity (detection range/cross-reactivity), a panel of genomic DNA extracted from large quantities (Ͼ10 6 organisms) of the following fungal genera/species was tested: Absidia spp., Cunninghamella spp., Rhizopus spp., Fusarium oxysporum, Fusarium dimerum, Scedosporium apiospermum, Scedosporium prolificans, Penicillium spp., Exophiala spp., Epidermophyton floccosum, Trichophyton mentagrophytes, Trichophyton tonsurans, Trichophyton rubrum, Microsporum spp., Aspergillus fumigatus (n ϭ 5), A. terreus (n ϭ 4), A. flavus (n ϭ 4), Aspergillus niger (n ϭ 2), Aspergillus glaucus, Aspergillus versicolor, Aspergillus ustus, Aspergillus candidus, C. albicans (n ϭ 5), C. krusei (n ϭ 5), C. glabrata (n ϭ 5), C. tropicalis (n ϭ 5), C. parapsilosis (n ϭ 2), Candida lusitaniae, Candida viswanathii, Candida kefyr, Saccharomyces cerevisiae, Bipolaris spp., Scopulariopsis brevicaulis, Cladosporium spp., Acremonium spp., and Blastoschizomyces capitatus.
PCR amplification and SERS detection. PCR-SERS testing was performed, according to the manufacturer's instructions, using 10 l of DNA template in a final reaction volume of 50 l, targeting the 18S rRNA and 28S rRNA genes, and generating an amplicon ranging from 200 to 500 bp, dependent on species. A no-template control (NTC) was included in every PCR run and, for experiments testing simulated samples, quantified plasmids containing the PCR target were included in order to assess PCR efficiency. To monitor for sample inhibition, a quantified amount of plasmid containing a potato gene was added, and a control PCR was performed. Given the low concentrations of fungal DNA in blood samples, the inhibition PCR was performed as a separate reaction to prevent competition for reagents that might occur if both the fungal and control PCR were performed in a single tube. In doing so, any potential reduction in the sensitivity of the Fungiplex assay was avoided. All testing was performed with the user blinded to the original identity of the sample. An overview of the process is shown in Fig. 2 . The total process, including extraction, was completed within one working day (8 h), with the PCR amplification-SERS analysis taking approximately 6 h to complete, and a hands-on time of approximately 1 to 2 h, including extraction, was needed. The results (positive, negative, or inhibitory) were interpreted automatically by the instrument, using a direct classical least-squares model of analysis, which requires no manual spectroscopic expertise.
Determination of clinical performance. Fungal PCR is offered as a routine diagnostic test for patients at high risk of developing IFD (1, 17) . On completion of the tests, NA extracts and surplus serum/plasma samples are retained for internal quality control and performance assessment purposes. A total of 195 NA extracts from 112 patients were tested by the Fungiplex assay. The patients were a combination of hematology patients (n ϭ 83), abdominal surgery patients (n ϭ 27), a renal transplant patient, and one patient suffering from chronic granulomatous disease. Fortyfour hematology patients received allogeneic stem cell transplantation. The basic patient demographics are shown in Table 3 . IFD was defined according to the revised EORTC/MSG criteria, with PCR not used in determining a diagnosis (3). Twenty-eight samples were from 14 patients diagnosed with proven/probable IA, and nine samples were from three cases of possible IA. Twenty-eight samples were from 15 patients with a proven IC diagnosis. One hundred thirty samples were from 80 patients having no evidence of fungal disease (NEF). The study was conducted as a retrospective anonymous case-control study to assess the performance of the Fungiplex assay, with no impact on patient management.
The NA extracts from patients previously tested by fungal PCR were tested by the Fungiplex assay with the user blinded to the previous PCR result and to the diagnosis of IFD (17) . NA was extracted from 0.5 ml plasma/serum using the Qiagen EZ1 DSP virus kit, or from 3 ml of WB according to EAPCRI recommendations combined with the Qiagen EZ1 tissue kit, with NA eluted in 50-to 60-l volumes (5, 6) . For all extractions, positive and negative extraction controls were incorporated at the time of extraction to monitor assay performance. On completion of the routine testing, the extracts were stored at Ϫ80°C before being tested by the Fungiplex assay. PCR testing was performed on these extracts as described above using the Applied Biosystems Veriti instrument, and an inhibition control was used for every sample. For every run-quantified plasmid, NTCs and simulated samples were included to assess PCR performance. On completion of the testing, the results were independently compared against the original diagnosis to determine assay performance.
Statistical analysis. To determine the validity of the Fungiplex assay results, the positivity rate of samples originating from cases was compared to the false-positivity rate of the control samples. To determine the clinical performance (sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio) of the Fungiplex assay, 2 by 2 tables were constructed, using both proven/probable IFD and proven/probable/possible IFD as true cases and NEF patients as the control population. For all patients, including those with multiple samples tested, only a single positive was required to consider the patient positive. Given the case-control study design and the artificially high prevalence of IFD (28.6%), predictive values were not used. Ninety-five percent confidence intervals were generated for each proportionate value and, where required, P values (Fisher's exact test; P ϭ 0.05) were used to determine the significance of the difference between the rates (18) . The agreement between the Fungiplex assay and the original real-time PCR results was determined by calculating the kappa statistic and observed agreement (17, 19) .
RESULTS

Limit of detection of PCR amplification and SERS detection.
The LOD of the PCR-SERS process was determined by identifying the lowest plasmid concentration that achieved a Ն95% reproducibility of detection, and this is summarized in Table 1 . When testing a plasmid input of 200 copies per PCR, 11 of the 12 plas- mids (eight Candida and four Aspergillus targets) achieved 100% reproducibility, with one target (C. parapsilosis) achieving 97.5% reproducibility. At the lower concentration of 20 input copies per reaction, six targets achieved the prerequisite 95% reproducibility limit, with four targets (C. glabrata, C. guilliermondii, C. lusitaniae, and C. tropicalis) achieving Ͼ90% reproducibility, and two targets (C. krusei and A. niger) achieving 80% and 82.5% reproducibility, respectively. The overall reproducibility for all targets at this input was 92.1% (95% confidence interval [CI], 89.3 to 94.2%). The 38 false-negative results were distributed evenly between the different PCR platforms used (Bio-Rad MyCycler, 10; Bio-Rad T100, 6; GRI G-Storm, 13; ABI Veriti, 9). At an input of two plasmid copies per reaction, reproducibility ranged from 1/9 (11.1%; 95% CI, 2.0 to 43.5%) for A. fumigatus and C. lusitaniae, to 5/9 (55.6%; 95% CI, 26.7 to 81.1%) for A. niger and C. guilliermondii, with an overall reproducibility of 37.0% (95% CI, 27.3 to 47.9%). At one input copy per reaction, the reproducibility was 11.1% for all targets.
Reproducibility of detection of the entire molecular process. The reproducibility of detection of the entire molecular process (NA extraction-PCR amplification-SERS detection) was determined by testing 93 simulated samples and is summarized in Table 2. At moderate (50 to 100 genomic equivalents [GE] per sample) and low (10 to 20 GE per sample) fungal burdens, the overall reproducibility of detection rates were 97.1% (95% CI, 85.1 to 99.5%) and 89.8% (95% CI, 79.5 to 95.3%), respectively, with no significant difference in performance between the different sam- a One replicate missed using the Bio-Rad MyCycler, and one replicate missed using the GRI G-Storm. b One replicate missed using the Bio-Rad MyCycler, and two replicates missed using the GRI G-Storm. c One replicate missed using the Bio-Rad MyCycler, two replicates missed using the Bio-Rad T100, and five replicates missed using the GRI G-Storm. d One replicate missed using the Bio-Rad MyCycler, and three replicates missed using the GRI G-Storm. e One replicate missed using the Applied Biosystems Veriti. f One replicate missed using the Bio-Rad MyCycler, and one replicate missed using the Bio-Rad T100. g One replicate missed using the Bio-Rad MyCycler, two replicates missed using the Bio-Rad T100, and one replicate missed using the Applied Biosystems Veriti. h Two replicates missed using the Bio-Rad MyCycler, and one replicate missed using the Applied Biosystems Veriti. i One replicate missed using the Bio-Rad T100. j For comparative purposes, the mean number of copies of the rRNA genes per genome of A. fumigatus is 54 (16 a For comparative purposes, the mean number of copies of the rRNA genes per genome of A. fumigatus is 54 (16) . Consequently, 10 genomes per sample equates to 540 copies per sample. When testing a sample with a 10 GE or conidial burden and assuming 100% extraction efficiency, combined with an elution volume of 60 l and a PCR template input volume of 10 l, the total input equals 90 copies or 1.6 GE/conidia per reaction. One A. fumigatus conidium contains one genome. ple types at either burden level (moderate burden, P ϭ 1.0; low burden, P ϭ 0.2199). Analytical specificity: detection range and cross-reactivity. In testing the robustness of the detection range, a total of 44 strains, comprising eight species of both Candida and Aspergillus, were tested. Five strains of both C. krusei and C. glabrata were correctly identified by their specific probes. All other species of Candida were detected by one or both of the generic probes. Four   FIG 2 Overview of the Fungiplex assay process. DNA is extracted from the clinical sample according to EAPCRI recommendations. PCR is performed using biotinylated oligonucleotides, after which the PCR products are subsequently denatured. Specific and optimized multiplex SERS probes are then added and, if DNA from a target organism is present, the appropriate probe is hybridized to the biotinylated PCR product. The samples are then transferred to the RenDx SP-1000 for automated processing. Labeled DNA is captured onto streptavidin-coated magnetic beads (via the biotin label), which are then immobilized, allowing the excess and residual probes to be removed by washing. The amplicon-probe complexes are then eluted and transferred to a clean 96-well detection plate, while the magnetic beads and attached DNA are discarded. At the final stage, the SERS detection reagents (silver colloidal suspension) are added and the plate is transferred to the SA-1000 for Raman spectroscopic analysis. The manual steps are in the boxes with dashed lines. The nucleic acid extraction step can be automated; this is dependent on the method used and sample tested. For whole-blood samples, when performed according to EAPCRI recommendations, the process is semiautomated (5). strains of A. terreus were correctly identified by the specific probe, and six of the seven remaining Aspergillus species were detected by the generic probe. A. ustus, despite being successfully amplified by PCR, did not generate a positive SERS signal, and the sequencing of the amplicon showed only 83.3% similarity with the generic Aspergillus probe. Potential cross-reactivity was noted for one of the 23 additional fungal species tested, with F. oxysporum cross-reacting with both the Saccharomycetales probe and the probe specific for pathogenic Candida (C. albicans, C. dubliniensis, C. parapsilosis, and C. tropicalis) . A sequence alignment of the oligonucleotides showed 90.9% and 86.4% similarities with the forward and reverse Candida primers, respectively, and 100% and 80.8% similarities with the Saccharomycetales and generic Candida probes, respectively. Repeat testing of the original DNA confirmed this finding. However, the sequencing of both amplicons provided an identification of C. parapsilosis, suggesting sampling error or contamination with C. parapsilosis DNA. This cross-reactivity was not seen with other Fusarium species tested. S. cerevisiae was also detected by the Saccharomycetales probe but was not considered cross-reactivity, as it is part of this order. An additional sequence alignment showed that potential cross-reactivity between Penicillium species and the Aspergillus assay and Trichosporon species and the generic Candida assay might occur. Upon testing Penicillium species, intermittent false positivity was noted, and further investigations are ongoing.
Clinical performance: sample positivity rates. Of the 28 samples originating from patients with IC, 18 generated a positive Candida SERS signal (positivity rate, 64.3%; 95% CI, 45.8 to 79.3%). For patients with proven/probable IA, the sample positivity rate was 20/28 (71.4%; 95% CI, 52.9 to 84.8%) compared to 2/9 (22.2%; 95% CI, 6.3 to 54.7%) for patients with possible IA. The overall positivity rate for the samples originating from cases of proven/probable IFD was 38/56 (69.7%; 95% CI, 54.8 to 78.6%), and for proven/probable/possible IFD, it was 40/65 (61.5%; 95% CI, 49.4 to 72.4%).
When testing serum, plasma, and WB samples, the positivity rates were 8/15 (53.3%; 95% CI, 30.1 to 75.2%), 20/28 (71.4%; 95% CI, 52.9 to 84.8%), and 10/13 (76.9%; 95% CI, 49.8 to 91.8%), respectively, for samples originating from cases of proven/probable IFD.
The false-positivity rate (i.e., a positive signal in the samples from NEF patients) was 12/130 (9.2%; 95% CI, 5.4 to 15.4%) and was significantly lower than the true positivity rates (Candida difference, 55.1%; 95% CI, 35.6 to 70.6%, P Ͻ 0.0001; Aspergillus difference, 62.2%; 95% CI, 42.7 to 76.1%; P Ͻ 0.0001; overall difference, 58.6%; 95% CI, 44.2 to 70.0%; P Ͻ 0.0001), showing a significant association between assay positivity and proven/probable IFD (P Ͻ 0.0001). False positivity was significantly greater in serum (9/34 [26.5%]) than in plasma (3/96 [3.1%]) (difference, 23.4%; 95% CI, 10.2 to 40.1%; P ϭ 0.0022) samples. No WB samples from NEF patients were tested. False positivity was split equally between Candida (n ϭ 6) and Aspergillus (n ϭ 5) organisms, with one sample generating a positive signal for both targets.
Clinical performance: concordance between PCR assays. The overall observed agreement between the original real-time PCR result and the retest RenDx result was 80.5% (95% CI, 73.4 to 87.6%), generating a kappa statistic of 0.552, representing moderate agreement between the assays (Table 4 Clinical performance parameters. The performance of the RenDx Fungiplex assay is summarized in Table 5 . The sensitivity was similar for detecting both Aspergillus (85.7%) and Candida (80.0%). The specificity was 87.5% and was improved (97.5%; 95% CI, 87.7 to 99.7%) by using a more stringent positivity threshold (Ն2 samples required to be RenDx Fungiplex positive), albeit at the expense of sensitivity (31.0%; 95% CI, 13.5 to 55.8%). The sensitivity varied with IC disease manifestation and was higher for cases of candidemia (100%; 95% CI, 64.6 to 100%) than for those from other IC infections, such as peritonitis or abdominal abscesses (62.5%; 95% CI, 30.6 to 86.3%), although the numbers were limited. Sensitivity also varied with sample type and was lowest when testing NA extracted from serum (53.3%; 95% CI, 30.1 to 75.2%), followed by WB (76.9%; 95% CI, 49.7 to 91.8%) and plasma (85.7%; 95% CI, 60.1 to 96.0%).
DISCUSSION
A preliminary clinical evaluation of the RenDx Fungiplex assay shows promising clinical performance, and it is coupled with the benefits of commercial manufacture to ISO13485, requiring a comprehensive quality management system for the design and manufacture of medical devices. The overall sensitivity of 82.8% (95% CI, 58.1 to 94.8%) for detecting cases of both IC and IA was not unduly influenced by the performance of either arm of the assay. The sensitivity for detecting cases of IA (85.7; 95% CI, 48.7 to 98.2%) was comparable to the sensitivities generated by metaanalyses evaluating the performance of Aspergillus PCR assays for testing both blood (88%) and bronchoalveolar lavage (BAL) fluid (79%) samples (20, 21) . The sensitivity for detecting cases of IC was 80.0% (95% CI, 44.6 to 96.0%) but was 100% (95% CI, 64.6 to 100%) for detecting cases of candidemia, similar to the results generated in a meta-analysis of Candida PCR, in which the sensitivity fell from 95 to 100% for candidemia to 73% for proven/ probable/possible IC (22) . When localized disease is suspected and the patient is not fungemic, testing samples specific to the particular site may be beneficial, as biomarker availability in the circulation may be limited. The specificity was 87.5% (95% CI, 74.7 to 94.5%), comparing favorably with the specificities determined in the various metaanalyses (range, 75% to 94%) (20) (21) (22) . False positivity was associated equally with the two pathogens (Candida, n ϭ 6; Aspergillus, n ϭ 5) but more with serum testing (P ϭ 0.0022). However, serum testing was associated with post-abdominal surgery patients, and it may be the patient population rather than the sample type causing this false positivity. Biomarker false positivity has been noted in this population, hypothetically associated with translocation of flora from the gastrointestinal (GI) tract. In the study by León et al. (23) , combining two biomarker assays improved sensitivity but reduced specificity compared to that for (1,3)-␤-D-glucan testing. In half of the false-positive cases generated by the Fungiplex assay, other biomarker assays were positive, perhaps representing undiagnosed disease. Specificity was increased by using a multiplepositive threshold (Ն2 samples positive), with only two cases generating two false-positive results, although this significantly compromises sensitivity (Table 5) .
The sensitivity as determined by retrospective analysis is likely too low for the assay to be used as a screening test. However, the Fungiplex assay performance may be further enhanced by a prospective evaluation. In the initial retrospective case-control study of the MycAssay Aspergillus assay, the sensitivity for testing serum samples was 60 to 70% but increased to 100% on prospective testing (9, 10) . The potential improvement in sensitivity through prospective evaluation maybe sufficient for the Fungiplex assay to be used as a screening assay to exclude IFD. Long-term storage of samples and the effect of freeze-thawing may result in the degradation of DNA. If DNA was already at a concentration close to the limit of reproducible real-time PCR detection when originally tested, degradation might result in false negativity on retesting. This might also explain why the concordance between the initial positive PCR results from the cases was lower than that for the negative PCR results from the controls. Unfortunately, the limited original NA eluate and availability of stored samples prevented further retesting. Consequently, in this study, it is not possible to determine if SERS detection provides superior sensitivity over real-time technology, as proposed elsewhere (14) . Being a casecontrol study, it is not designed to determine the clinical utility of the Fungiplex assay, and a prospective cohort study is required to provide accurate clinical validity and utility.
A major strength of the evaluation is that it is in accordance with the EAPCRI recommendations for the extraction of fungal DNA from whole blood and serum, allowing a standardized approach for both sample processing and, through commercial manufacture of the Fungiplex assay, PCR detection. The commercial kits are quality controlled, and the methodology is standardized in line with other commercial fungal biomarker tests (galactomannan [GM] enzyme-linked immunosorbent assay [ELISA] and [1, 3] -␤-D-glucan). Analytical performance should therefore be robust across study centers, providing identical performance without local optimization and expertise required to develop an in-house test. Several commercial assays are available, although most target either an individual fungal pathogen (MycAssay Aspergillus and T2MR Candida) or, despite targeting both Candida and Aspergillus, have received validation for one pathogen only (Roche SeptiFast) (8) (9) (10) (11) (12) . The Fungiplex assay has received validation for both targets and has the added benefit of being an open platform with broad multiplexing capacity (currently up to 10 targets), allowing the user to develop bespoke assays targeting other fungal pathogens, as directed by local epidemiology.
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